NCT04679909

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Altimmune, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
BIOLOGICAL	AdCOVID	Administered intranasally
OTHER	Placebo	Administered intranasally

Timeline

• Start date: 2021-02-25
• Primary completion: 2021-12-01
• Completion: 2022-12-21
• First posted: 2020-12-22
• Last updated: 2023-08-14

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study